Director, Investigative Sciences

The Investigative Sciences team within Early Development at Alnylam is seeking an experienced and highly motivated Associate Director / Director to lead interdisciplinary mechanistic efforts related to nonclinical safety assessment of oligonucleotide therapeutics and their targets. The role requires a track record in successfully addressing cellular/biochemical mechanisms of drug-related toxicities. A solid foundation in immunology is preferred. The candidate will engage in cross-functional efforts to derisk novel oligonucleotide constructs conjugated to a variety of ligands, including antibodies, peptides, and small molecules, will be responsible for addressing mechanisms of toxicities across tissues, and will lead early target safety assessment across the portfolio.

This position is onsite and will be located in Cambridge, MA.

Key Responsibilities

* Drive strategy and execution of novel oligonucleotide conjugate derisking efforts, including immunotoxicity and immunogenicity
* Drive highly innovative cellular/biochemical toxicology research into mechanisms of oligonucleotide toxicities across tissues
* Lead early target safety assessment strategy and execution across the portfolio
* Establish productive cross-functional collaborations with Regulatory Toxicology, Pathology, DMPK, Bioanalysis, and Research groups
* Effectively communicate with management and project teams
* Supervise and develop a team of scientists

Qualifications

* Ph.D. in Immunology and/or Cellular Toxicology or a related field, with 10+ years of experience in industry or academia; DABT certification is a plus
* Experience in nonclinical safety assessment of antibodies and/or peptides
* Track record in successfully addressing cellular/biochemical mechanisms of drug-related toxicities
* Strong interpersonal skills, and excellent organization, team management, and communication skills are required
* Familiarity with oligonucleotides is preferred

About Alnylam:Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture:Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law.